Abstract
In the recent years, the existence of cardiac regeneration in mammalian models and even humans has been confirmed in several, carefully designed and executed studies. However, the intrinsic rate of cardiomyocyte renewal is not sufficient to replenish the large number of cells lost after a major injury in the heart, such as myocardial infarction. Therefore, exogenously administered cells with progenitor properties have been used in order to augment this process. From the several candidate cell populations, cardiac derived progenitor cells appear particularly attractive for this purpose, based on data from many experimental studies but also preliminary clinical applications. Cardiosphere-derived cells are a mixed cell population that has shown great potential in stimulating endogenous mechanisms of cardiac repair and attenuating adverse remodeling of the heart. In the present review, we discuss in detail the existing evidence regarding the therapeutic role of cardiosphere-derived progenitor cell administration in the post-myocardial infarction setting. Proof-of-concept studies in rodents, as well as more clinically relevant experiments in large animal models, have provided consistent results regarding the potential of these cells to improve cardiac structure and function after myocardial infarction. Existing data about the underlying mechanisms that are implicated in myocardial regeneration triggered by these cells are presented, as well as preliminary data from clinical applications and future perspectives of this novel therapeutic option.
Keywords: Cardiac regeneration, cardiosphere-derived cells, c-kit+, myocardial infarction, remodeling.
Current Pharmaceutical Design
Title:Cardiosphere-derived Progenitor Cells for Myocardial Repair Following Myocardial Infarction
Volume: 20 Issue: 12
Author(s): Vasilios Sousonis, John Nanas and John Terrovitis
Affiliation:
Keywords: Cardiac regeneration, cardiosphere-derived cells, c-kit+, myocardial infarction, remodeling.
Abstract: In the recent years, the existence of cardiac regeneration in mammalian models and even humans has been confirmed in several, carefully designed and executed studies. However, the intrinsic rate of cardiomyocyte renewal is not sufficient to replenish the large number of cells lost after a major injury in the heart, such as myocardial infarction. Therefore, exogenously administered cells with progenitor properties have been used in order to augment this process. From the several candidate cell populations, cardiac derived progenitor cells appear particularly attractive for this purpose, based on data from many experimental studies but also preliminary clinical applications. Cardiosphere-derived cells are a mixed cell population that has shown great potential in stimulating endogenous mechanisms of cardiac repair and attenuating adverse remodeling of the heart. In the present review, we discuss in detail the existing evidence regarding the therapeutic role of cardiosphere-derived progenitor cell administration in the post-myocardial infarction setting. Proof-of-concept studies in rodents, as well as more clinically relevant experiments in large animal models, have provided consistent results regarding the potential of these cells to improve cardiac structure and function after myocardial infarction. Existing data about the underlying mechanisms that are implicated in myocardial regeneration triggered by these cells are presented, as well as preliminary data from clinical applications and future perspectives of this novel therapeutic option.
Export Options
About this article
Cite this article as:
Sousonis Vasilios, Nanas John and Terrovitis John, Cardiosphere-derived Progenitor Cells for Myocardial Repair Following Myocardial Infarction, Current Pharmaceutical Design 2014; 20 (12) . https://dx.doi.org/10.2174/13816128113199990445
DOI https://dx.doi.org/10.2174/13816128113199990445 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Nuclear Imaging of Post-infarction Inflammation in Ischemic Cardiac Diseases - New Radiotracers for Potential Clinical Applications
Current Radiopharmaceuticals Role of Nitric Oxide and Mitochondrial Nitric Oxide Synthase in Energy Adaptive Responses
Current Cardiology Reviews Hypothyroidism and Endothelial Function: A Marker of Early Atherosclerosis?
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Gene Therapy Approaches for Cardiovascular Diseases
Current Gene Therapy MicroRNAs and Peroxisome Proliferator-Activated Receptors Governing the Differentiation of Mesenchymal Stem Cells
Current Stem Cell Research & Therapy Performance Improvement of Gene Selection Methods using Outlier Modification Rule
Current Bioinformatics Quinone-Based Drugs: An Important Class of Molecules in Medicinal Chemistry
Medicinal Chemistry Role of α- and β-adrenergic Mechanisms in the Pathogenesis of Pulmonary Injuries Characterized by Edema, Inflammation and Fibrosis
Cardiovascular & Hematological Disorders-Drug Targets Innate Immunity and the Heart
Current Pharmaceutical Design Unfolding Cardiac Amyloidosis –From Pathophysiology to Cure
Current Medicinal Chemistry The Potential of Secondary Metabolites from Plants as Drugs or Leads Against Protozoan Neglected Diseases – Part I
Current Medicinal Chemistry Anesthetic Pharmacology and Perioperative Considerations for Heart Transplantation
Current Clinical Pharmacology Clinical Management of Arrhythmogenic Right Ventricular Cardiomyopathy: An Update
Current Pharmaceutical Design Endothelial Progenitors in Vascular Repair and Angiogenesis: How Many are Needed and What to do?
Cardiovascular & Hematological Disorders-Drug Targets Efficacy and Complications of Subcutaneous <i>versus</i> Conventional Cardioverter Defibrillators: A Systematic Review and Meta-analysis
Current Cardiology Reviews Stem Cell Therapy in Chronic Ischemic Heart Dysfunction with and Without Viability
Cardiovascular & Hematological Disorders-Drug Targets Emerging Potential of Natural Products as an Alternative Strategy to Pharmacological Agents Used Against Metabolic Disorders
Current Drug Metabolism Role of Oxidative-Nitrosative Stress and Downstream Pathways in Various Forms of Cardiomyopathy and Heart Failure
Current Vascular Pharmacology Approaches Used in Immunotherapy for Prostate Cancer
Current Cancer Therapy Reviews Tako-tsubo Cardiomyopathy: A Review of the Literature
Current Cardiology Reviews